DK2833914T3 - Adjuvanssystem til oral vaccineadministration - Google Patents

Adjuvanssystem til oral vaccineadministration Download PDF

Info

Publication number
DK2833914T3
DK2833914T3 DK13772028.0T DK13772028T DK2833914T3 DK 2833914 T3 DK2833914 T3 DK 2833914T3 DK 13772028 T DK13772028 T DK 13772028T DK 2833914 T3 DK2833914 T3 DK 2833914T3
Authority
DK
Denmark
Prior art keywords
adjuvant
antigen
aluminum
well
ctl
Prior art date
Application number
DK13772028.0T
Other languages
English (en)
Inventor
Garry Morefield
Original Assignee
Vaxform Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxform Llc filed Critical Vaxform Llc
Application granted granted Critical
Publication of DK2833914T3 publication Critical patent/DK2833914T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Claims (8)

1. Immunologisk sammensætning til oral administration, der omfatter én eller flere C-type lectin- (CTL) receptorligander, ét eller flere aluminiumsadjuvanser og ét eller flere antigener og én eller flere acrylharpikspolymerer.
2. Immunologisk sammensætning ifølge krav 1, hvor acrylharpikspolymeren er en vandopløselig copolymer af ethylacrylat (EA), methylmethacrylat (MM) og trimethylammoniumethyl-methacrylatchlorid.
3. Immunologisk sammensætning ifølge krav 1, der endvidere omfatter et frostbeskyttelsesadditiv, eventuelt hvor frostbeskyttelsesadditivet er valgt fra gruppen bestående af trehalose, mannitol, lactose, sorbitol og saccharose og kombinationer deraf.
4. Fremgangsmåde til fremstilling af en oralt administrerbar immunogen sammensætning, der omfatter: adsorbering af et antigen og en C-type lectin- (CTL) receptorligand til et aluminiumsadjuvans; tilsætning af en acrylharpikspolymer med pH-afhængig opløselighed for at danne en vaccineformulering og tilsætning af vaccineformuleringen til opløsning med lavt pH for at præcipitere polymeren, hvorved der dannes en oralt administrerbar immunogen sammensætning.
5. Fremgangsmåde ifølge krav 4, hvor aluminiumsadjuvansen er aluminiumoxyhydroxid.
6. Fremgangsmåde ifølge krav 4, hvor CTL-receptorliganden er et saccharid.
7. Fremgangsmåde ifølge krav 4, hvor acrylharpiksen er en vanduopløselig copolymer af ethylacrylat (EA), methylmethacrylat (MM) og trimethylammoniumethyl-methacrylatchiorid.
8. Fremgangsmåde ifølge krav 4, der endvidere omfatter trinnet med atmosfærisk sprøjtefrysetørring af den oralt administrerbare immunogene sammensætning.
DK13772028.0T 2012-04-04 2013-04-03 Adjuvanssystem til oral vaccineadministration DK2833914T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261686372P 2012-04-04 2012-04-04
PCT/US2013/000102 WO2013151595A1 (en) 2012-04-04 2013-04-03 Improved adjuvant system for oral vaccine adminstration

Publications (1)

Publication Number Publication Date
DK2833914T3 true DK2833914T3 (da) 2019-03-11

Family

ID=49300897

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13772028.0T DK2833914T3 (da) 2012-04-04 2013-04-03 Adjuvanssystem til oral vaccineadministration

Country Status (10)

Country Link
US (3) US20150079130A1 (da)
EP (2) EP3549605A1 (da)
JP (1) JP6240155B2 (da)
KR (1) KR101867428B1 (da)
AU (1) AU2013243971B2 (da)
CA (1) CA2903313C (da)
DK (1) DK2833914T3 (da)
IL (1) IL234937B (da)
MX (1) MX364946B (da)
WO (1) WO2013151595A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL247301B (en) * 2014-02-20 2022-07-01 Vaxart Inc Formulations for administration to the small intestine
CA2988165C (en) * 2014-06-20 2023-08-01 University Of Saskatchewan Exotoxin/thermolysin compositions and methods and uses for treating or preventing laminitis
MX2018010858A (es) * 2016-03-07 2019-05-22 Glaxosmithkline Biologicals Sa Particulas de liberacion de farmacos.
KR102369740B1 (ko) 2020-09-21 2022-03-02 부경대학교 산학협력단 자궁경부암 조기진단을 위한 모바일 질확대경 장치
CN113750228B (zh) * 2021-09-25 2024-02-20 大连理工大学 一种冷冻保护剂在铝佐剂中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4133397A (en) * 1996-10-28 1998-05-22 Pfizer Inc. Oral vaccines for young animals with an enteric coating
ES2232934T3 (es) * 1997-02-14 2005-06-01 MERCK & CO., INC. Formulaciones de vacunas a base de polinucleotidos.
US7087235B2 (en) 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
US20030162955A1 (en) * 1998-03-17 2003-08-28 Lionel Chalus Isolated mammalian membrane protein genes; related reagents
HUP0103396A3 (en) * 1998-07-08 2002-05-28 Kirin Amgen Inc Wilmington Powdery preparation for mucosal administration containing polymeric medicine
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
WO2004018698A2 (en) * 2002-08-20 2004-03-04 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
JP2006518748A (ja) * 2003-02-20 2006-08-17 ベクトン・ディキンソン・アンド・カンパニー 改良されたワクチン接種のための大気圧噴霧凍結乾燥によって作製される組換えブドウ球菌エンテロトキシンｂ（＜ｓｂ＞ｒ＜／ｓｂ＞ｓｅｂ）の粉末処方物
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
EP2066348A1 (en) * 2006-09-26 2009-06-10 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
JP5911799B2 (ja) * 2009-08-12 2016-04-27 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ポリマーマトリックスおよび油相を含んで成る免疫調節組成物
GB0919690D0 (en) * 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201101665D0 (en) * 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions

Also Published As

Publication number Publication date
AU2013243971B2 (en) 2017-01-05
US20210052725A1 (en) 2021-02-25
CA2903313C (en) 2019-10-22
AU2013243971A1 (en) 2014-10-02
JP6240155B2 (ja) 2017-11-29
EP2833914A1 (en) 2015-02-11
WO2013151595A1 (en) 2013-10-10
KR101867428B1 (ko) 2018-07-19
MX2014011806A (es) 2015-06-03
IL234937B (en) 2021-10-31
KR20150002755A (ko) 2015-01-07
EP2833914B1 (en) 2019-01-16
EP2833914A4 (en) 2016-03-30
MX364946B (es) 2019-05-15
EP3549605A1 (en) 2019-10-09
US20150079130A1 (en) 2015-03-19
IL234937A0 (en) 2014-12-31
US20190105389A1 (en) 2019-04-11
CA2903313A1 (en) 2013-10-10
JP2015512441A (ja) 2015-04-27

Similar Documents

Publication Publication Date Title
US20210052725A1 (en) Adjuvant system for oral vaccine administration
US20230234850A1 (en) Adjuvanted vaccines
US20070237826A1 (en) Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides
JP2011514337A (ja) 糖ガラス化ウィルス様粒子（ｖｌｐ）
US10736952B2 (en) Multivalent VLP conjugates
JP2010105968A (ja) カチオン性ナノゲルを用いる粘膜ワクチン
CN114340665A (zh) 用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法
US9216215B2 (en) Adjuvant system for vaccine adjuvant
US20200405849A1 (en) Vaccine system for vaccine adjuvant
Hendy Improved Delivery of a Broadly Active Influenza Subunit Vaccine
Beukema Intradermal administration of influenza accine ith trehalose and pullulan-based dissol ing microneedle arra s
Hassett Ultra stable glassy state vaccines containing adjuvants
Lu EVALUATION OF ALPHA-D-GLUCAN NANOPARTICLE AS A VACCINE ADJUVANT